生物技术公司Kymera Therapeutics（KYMR）今日盘中股价大跌8.33%，主要原因是该公司发布的第二季度财报显示业绩不及市场预期。
根据公司公布的财报，截至6月30日的季度内，Kymera Therapeutics调整后每股亏损95美分，远低于分析师平均预期的81美分亏损。公司营收为1148万美元，同比下降55.3%，同样未达到分析师预期的2339万美元。此外，公司本季度净亏损高达7661万美元，这些数据均显示公司当前面临着严峻的经营挑战。
尽管公司业绩表现不佳，但华尔街分析师对Kymera Therapeutics的长期前景仍保持乐观态度。目前，分析师对该公司股票的平均评级为"强力买入"，12个月目标价中位数为60.00美元，较上次收盘价40.62美元高出约32.3%。然而，投资者仍需谨慎关注公司未来的业绩表现和产品研发进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.